Emily Martin, MD
Endocrinology, Diabetes & Metabolism · Butler, PANPI 1235344250
Payments from drug & device makers
Across 683 payments — averaging $333.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$219K
- Cequr Corporation$2K
- Lilly USA, LLC$1K
- AstraZeneca$751
- Sanofi-aventis U.S. LLC$398
- Medtronic$394
- plus $4K from 36 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 317 | $218,871 |
| Cequr Corporation | 4 | $1,825 |
| Lilly USA, LLC | 91 | $1,352 |
| AstraZeneca(2 entities) | 26 | $751 |
| Sanofi-aventis U.S. LLC | 26 | $398 |
| Medtronic(2 entities) | 9 | $394 |
| Amgen | 16 | $365 |
| Boehringer Ingelheim | 21 | $361 |
| BD | 11 | $276 |
| BETA Bionics, Inc. | 10 | $255 |
| Tandem Diabetes Care, Inc. | 11 | $225 |
| Bayer | 11 | $191 |
| Dexcom, Inc. | 9 | $191 |
| Johnson & Johnson | 13 | $188 |
| AbbVie | 10 | $184 |
| IBSA Pharma Inc. | 8 | $157 |
| Insulet Corporation | 9 | $144 |
| Abbott | 9 | $144 |
| Amneal Pharmaceuticals LLC | 7 | $131 |
| Xeris Pharmaceuticals, Inc. | 6 | $107 |
| Amarin Pharma, Inc. | 7 | $105 |
| Amphastar Pharmaceuticals, Inc. | 5 | $84 |
| Embecta Corp. | 3 | $75 |
| Ascendis Pharma Endocrinology Inc | 4 | $70 |
| Merck | 5 | $69 |
| Shire North American Group Inc | 4 | $63 |
| Antares Pharma, Inc. | 4 | $63 |
| Neurocrine Biosciences, Inc. | 3 | $59 |
| Corcept Therapeutics | 4 | $54 |
| Radius Health, Inc. | 3 | $54 |
| Madrigal Pharmaceuticals | 2 | $48 |
| Smith+Nephew | 2 | $40 |
| Kyowa Kirin, Inc. | 2 | $32 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Valeritas, Inc. | 1 | $20 |
| Soleno Therapeutics, Inc. | 1 | $20 |
| Lifescan, Inc. | 1 | $18 |
| Alvogen Inc | 1 | $17 |
| Sequel Med Tech, LLC | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Kvk-tech, Inc. | 3 | $13 |
How this compares
$227,487 in reported general payments places this provider in the 90th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Butler
- Sanjay DixitButler$42K
- Mona Al MukaddamPhiladelphia$3.9M
- Serge JabbourPhiladelphia$3.1M
- Mihaela BiscoveanuPhiladelphia$1.5M
- Barbara SimonPhiladelphia$1M
- Mitchell LazarPhiladelphia$1M
- Vijay BahlPittsburgh$998K
- Intekhab AhmedPhiladelphia$926K
- Erin KershawPittsburgh$804K
- Geraldo SaavedraWhitehall$698K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.